SEC Charges Acadia Pharma Executive With Insider Trading

George Demos, former Vice President of Drug Safety at Acadia Pharmaceuticals, was charged March 7 with trading company stock based on confidential information about an adverse FDA decision. The charges cite violations of securities laws. FDA rulings move pharma stock prices sharply, giving insiders a substantial timing advantage.